Influence of time horizon and treatment patterns on cost-effectiveness measures: The case of allergen-specific immunotherapy with Grazax

Journal of Medical Economics

Volumn 10, Issue 3, 2007, Pages 215-228

  Bériot Mathiot, Axeile ^a   Vestenbæk, Ulrik ^b   Poulsen, Peter Bo ^a,c  

^a MUUSMANN Research and Consulting   (Denmark)

^b ALK ABELLÓ   (Denmark)

^c MUUSMANN Research and Consulting   (Denmark)

Author keywords

Allergen specific immunotherapy; Cost effectiveness; Costs; QALYs; Rhinoconjunctivitis

Indexed keywords

ALLERGEN; GRASS POLLEN ALLERGEN; GRAZAX; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT CARE; POLLEN ALLERGY; RHINOCONJUNCTIVITIS; SEASONAL VARIATION; SWEDEN; TREATMENT INDICATION; WORLD HEALTH ORGANIZATION;

EID: 34748852517     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990701438587     Document Type: Article

References (22)

1. Bousquet J, van Cauwenberge P, Khaltaev N et al. Allergic rhinitis and its impact on asthma. Journal of Allergy and Clinical Immunology 2001; 108(Suppl 5): S147-S334.
2. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. European Respiratory Journal 2004; 24: 758-764.
3. Canonica GW. Introduction. Expanding the anti-allergy therapeutic horizon. Allergy 2002; 57(Suppl 75): 5-7.
4. Swedish Medical Products Agency. Läkemedelsverket. Behandling av allergisk rinit. Behandlingsrekommendation, 28 Maj 2003.
5. Bousquet J, Lockey R, Mailing HJ et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Annals of Allergy, Asthma & Immunology 1998; 81: 401-405.
6. Alvarez-Cuesta E, Bousquet J, Canonica GW et al. EAACI Immunotherapy Task Force. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61(Suppl 82): 120.
7. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen allergen specific immunotherapy. New England Journal of Medicine 1999; 34: 468-475.
8. Mosbech H, Østerballe O. Does the effect of allergen specific immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988; 43: 523-529.
9. Di-Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual allergen specific immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clinical and Experimental Allergy 2003; 33: 206-210.
10. ALK-Abelló A/S, data on file, presented at the American Academy of Allergy, Asthma & Immunology (AAAAI), 2007.
11. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology. 2006; 118: 434-440.
12. Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). Decided on 24 April 2003.
13. Drummond MF, Sculpher MJ, Torrance GW et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford, UK: Oxford Medical Publications, 2005.
14. Lönestatistisk årsbok 2003. Statistics Sweden. Available at: http://www.scb.se [accessed 24 January 2007].
15. Briggs A, Nixon R, Dixon S et al. Parametric modelling of cost data: some simulation evidence. Health Economics 2005; 14:421-428.
16. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? British Medical Journal 2000; 320: 1197-1200.
17. Swedish Pharmaceutical Benefits Board. Läkemedelsförmå nsnämnden (LFN). Kostnadseffektiva läkemedel. Available at: http://www.lfn.se [accessed 24 January 2007].
18. The Swedish Medical Association. Sveriges läkarförbund, etableringsregler. http://www.lakarforbundet.se [accessed 24 January 2007].
19. Swedish National Board of Health and Welfare (Socialstyrelsen). Available at: http://www.socialstyrelsen.se [accessed 24 January 2007].
20. European Federation of Allergy and Airway Diseases Patients Association. Results of the patient voice allergy survey. Impact of allergic rhinitis in Europe. Summary Report (2005). http://www.efanet.org/ [accessed 24 January 2007].
21. National Institute of Clinical Excellence. Guide to the Methods of Technology Appraisal. London, UK: National Institute of Clinical Excellence 2004.
22. Donahue JG, Greineder DK, Connor-Lacke L et al. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Annals of Allergy, Asthma & Immunology 1999; 82: 339-347.